Efficacy of Xuanbai Chengqi decoction combined with western medicine in treating AECOPD with phlegm-heat obstructing lung syndrome: a clinical study.

IF 2.5 4区医学 Q3 ALLERGY

Allergologia et immunopathologia Pub Date : 2025-03-01 eCollection Date: 2025-01-01 DOI:10.15586/aei.v53i2.1180

Quan He, Guangfei Wei, Xuzhi Lu, Weiqi Feng, Meiyue Yu, Xiaomei Ma

{"title":"Efficacy of Xuanbai Chengqi decoction combined with western medicine in treating AECOPD with phlegm-heat obstructing lung syndrome: a clinical study.","authors":"Quan He, Guangfei Wei, Xuzhi Lu, Weiqi Feng, Meiyue Yu, Xiaomei Ma","doi":"10.15586/aei.v53i2.1180","DOIUrl":null,"url":null,"abstract":"Objective: To explore the efficacy of Xuanbai Chengqi Decoction combined with conventional Western medicine in the treatment of AECOPD patients with phlegm-heat obstructing the lung syndrome.Methods: A retrospective analysis was conducted on the clinical data of 166 patients with this syndrome admitted to our hospital between December 2023 and March 2024. Patients were divided into a study group (Xuanbai Chengqi Decoction + conventional Western medicine treatment, 83 cases) and a control group (conventional Western medicine treatment, 83 cases). The clinical efficacy, Traditional Chinese Medicine (TCM) syndrome scores, blood routine indicators, inflammatory factors, and other clinical outcomes were compared between the two groups.Results: Before treatment, there were no significant differences in the above-mentioned indicators between the two groups (P > 0.05). After treatment, the study group showed a significantly higher overall effective treatment rate, lymphocyte percentage, SOD, and NO levels, and a significantly lower TCM syndrome score, neutrophil percentage, white blood cell count, TNF-α, IL-6, CRP, and MOD levels, with statistical significance (P < 0.05).Conclusion: Xuanbai Chengqi Decoction combined with Western medicine treatment can effectively alleviate the clinical symptoms of AECOPD patients with phlegm-heat obstructing the lungs syndrome, improve blood routine indicators, control inflammation, and enhance the overall therapeutic effect.","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"100-107"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i2.1180","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore the efficacy of Xuanbai Chengqi Decoction combined with conventional Western medicine in the treatment of AECOPD patients with phlegm-heat obstructing the lung syndrome.

Methods: A retrospective analysis was conducted on the clinical data of 166 patients with this syndrome admitted to our hospital between December 2023 and March 2024. Patients were divided into a study group (Xuanbai Chengqi Decoction + conventional Western medicine treatment, 83 cases) and a control group (conventional Western medicine treatment, 83 cases). The clinical efficacy, Traditional Chinese Medicine (TCM) syndrome scores, blood routine indicators, inflammatory factors, and other clinical outcomes were compared between the two groups.

Results: Before treatment, there were no significant differences in the above-mentioned indicators between the two groups (P > 0.05). After treatment, the study group showed a significantly higher overall effective treatment rate, lymphocyte percentage, SOD, and NO levels, and a significantly lower TCM syndrome score, neutrophil percentage, white blood cell count, TNF-α, IL-6, CRP, and MOD levels, with statistical significance (P < 0.05).

Conclusion: Xuanbai Chengqi Decoction combined with Western medicine treatment can effectively alleviate the clinical symptoms of AECOPD patients with phlegm-heat obstructing the lungs syndrome, improve blood routine indicators, control inflammation, and enhance the overall therapeutic effect.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergologia et immunopathologia 医学-过敏

CiteScore

3.70

自引率

0.00%

发文量

131

审稿时长

6-12 weeks

期刊介绍： Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.